Alvotech has received FDA approval to use either of its two Reykjavik drug substance suites for the U.S. commercial supply of AVT02 (SIMLANDI), effectively doubling its manufacturing capacity. This approval also confirms the resolution of prior FDA inspection-related issues at the Reykjavik site, removing a potential overhang for the company.
Alvotech announced that the FDA has approved its Reykjavik site to manufacture AVT02 (SIMLANDI) drug substance for U.S. commercial supply from either of its two suites, effectively doubling its capacity. This is a significant positive development as it ensures a robust supply chain for its Humira biosimilar, SIMLANDI, which is a key product for the company. The approval also confirms that all FDA inspection-related matters at the Reykjavik site have been resolved, removing a previous regulatory hurdle and de-risking future operations. For traders, this means increased confidence in Alvotech's ability to meet demand and potentially gain market share, while for AbbVie, the originator of Humira, it signals intensified competition in the biosimilar market. Short-term, this could lead to a positive sentiment boost for ALVO; long-term, it strengthens its competitive position.